EMPA-M 12.5/500 EMPAGLIFLOZIN /METFORMIN 14’S

Empa-M 12.5/500 is a combination medication containing Empagliflozin and Metformin, primarily used for the management of type 2 diabetes mellitus. Empagliflozin is an SGLT2 inhibitor that helps lower blood sugar levels by preventing glucose reabsorption in the kidneys, promoting its excretion through urine. Metformin, on the other hand, is a biguanide that enhances insulin sensitivity, reduces hepatic glucose production, and improves glucose uptake by tissues. Together, these two active ingredients work synergistically to control blood sugar levels effectively.

In Kenya, Empa-M 12.5/500 is prescribed to help patients achieve better glycemic control, reduce the risk of diabetes-related complications, and improve overall metabolic health. It is particularly beneficial for overweight individuals with type 2 diabetes, as it also aids in weight management. Regular use, alongside a balanced diet and exercise, can significantly enhance the quality of life for diabetic patients.